Oragenics Launches Animal Study For COVID-19 Vaccine Candidate

Oragenics Inc OGEN has initiated a hamster challenge study to evaluate the immunogenicity and viral load reduction impact of its COVID-19 vaccine candidate.
Related Content: Oragenics's New Preclinical Data Supports Its Approach For COVID-19 Vaccine Development.
The study will provide data for several vaccine formulations, using adjuvants specific for both intranasal and intramuscular routes of administration.
An assessment of cross-neutralization titers against the Wuhan, Beta, and Delta variants of COVID-19 and reduction in the viral load of the Wuhan challenge virus will be used to establish the most promising formulations to advance to human clinical studies.
The study is being conducted by the Company's Canadian collaborator, with results expected in November.
Price Action: OGEN stock is down 1.54% at $0.64 during the market session on the last check Wednesday.